Literature DB >> 21254181

Hepatitis C pharmacogenetics: state of the art in 2010.

Nezam H Afdhal1, John G McHutchison, Stefan Zeuzem, Alessandra Mangia, Jean-Michel Pawlotsky, Jeffrey S Murray, Kevin V Shianna, Yasuhito Tanaka, David L Thomas, David R Booth, David B Goldstein.   

Abstract

In 2009, a correlated set of polymorphisms in the region of the interleukin-28B (IL28B) gene were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon-alfa and ribavirin. The same polymorphisms were subsequently associated with spontaneous clearance of HCV in untreated patients. The link between IL28B genotype and HCV clearance may impact decisions regarding initiation of current therapy, the design and interpretation of clinical studies, the economics of treatment, and the process of regulatory approval for new anti-HCV therapeutic agents.
Copyright © 2010 American Association for the Study of Liver Diseases.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21254181     DOI： 10.1002/hep.24052

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


  48 in total

Review 1.  Treatment of non-genotype 1 hepatitis C virus patients.

Authors:  Alessandra Mangia; Leonardo Mottola
Journal:  Curr Gastroenterol Rep       Date:  2012-02

2.  Utility of IL-28B Polymorphisms in the Era of Direct-Acting Antiviral Therapy.

Authors:  Stuart C Gordon
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-08

3.  Impact of host responses on control of hepatitis C virus infection in Chinese blood donors.

Authors:  Tingting Li; Zixuan Chen; Jinfeng Zeng; Jingang Zhang; Wenjing Wang; Ling Zhang; Xin Zheng; Lifang Shuai; Paul Klenerman; Jean-Pierre Allain; Chengyao Li
Journal:  Biochem Biophys Res Commun       Date:  2011-10-29       Impact factor: 3.575

4.  Studying the clinical encounter with the Adaptive Leadership framework.

Authors:  Donald E Bailey; Sharron L Docherty; Judith A Adams; Dana L Carthron; Kirsten Corazzini; Jennifer R Day; Elizabeth Neglia; Marcus Thygeson; Ruth A Anderson
Journal:  J Healthc Leadersh       Date:  2012-08

Review 5.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

Review 6.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

Review 7.  Predictive factors associated with hepatitis C antiviral therapy response.

Authors:  Lourianne Nascimento Cavalcante; André Castro Lyra
Journal:  World J Hepatol       Date:  2015-06-28

Review 8.  Chronic hepatitis C genotype 1 virus: who should wait for treatment?

Authors:  Cristiane Valle Tovo; Angelo Alves de Mattos; Paulo Roberto Lerias de Almeida
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 9.  Individualization of chronic hepatitis C treatment according to the host characteristics.

Authors:  Nikolaos K Gatselis; Kalliopi Zachou; Asterios Saitis; Maria Samara; George N Dalekos
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 10.  Current and future therapies for hepatitis C virus infection.

Authors:  T Jake Liang; Marc G Ghany
Journal:  N Engl J Med       Date:  2013-05-16       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.